CN113754665B - Preparation method of nucleoside compound - Google Patents
Preparation method of nucleoside compound Download PDFInfo
- Publication number
- CN113754665B CN113754665B CN202110621245.6A CN202110621245A CN113754665B CN 113754665 B CN113754665 B CN 113754665B CN 202110621245 A CN202110621245 A CN 202110621245A CN 113754665 B CN113754665 B CN 113754665B
- Authority
- CN
- China
- Prior art keywords
- acid
- alkyl
- reaction
- synthetic method
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 nucleoside compound Chemical class 0.000 title claims abstract description 31
- 239000002777 nucleoside Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title description 15
- 238000006243 chemical reaction Methods 0.000 claims abstract description 67
- 150000001875 compounds Chemical class 0.000 claims abstract description 27
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 8
- 150000002148 esters Chemical class 0.000 claims abstract description 5
- 150000007524 organic acids Chemical class 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 57
- BRDWIEOJOWJCLU-LTGWCKQJSA-N GS-441524 Chemical compound C=1C=C2C(N)=NC=NN2C=1[C@]1(C#N)O[C@H](CO)[C@@H](O)[C@H]1O BRDWIEOJOWJCLU-LTGWCKQJSA-N 0.000 claims description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 17
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 16
- 238000010189 synthetic method Methods 0.000 claims description 14
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 235000019253 formic acid Nutrition 0.000 claims description 9
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000012024 dehydrating agents Substances 0.000 claims description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
- 238000006482 condensation reaction Methods 0.000 claims description 6
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 6
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 claims description 6
- 238000010511 deprotection reaction Methods 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 4
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 claims description 3
- 125000005002 aryl methyl group Chemical group 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 8
- 238000003786 synthesis reaction Methods 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 5
- 238000009776 industrial production Methods 0.000 abstract description 4
- 238000003912 environmental pollution Methods 0.000 abstract description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract description 3
- 230000002194 synthesizing effect Effects 0.000 abstract description 3
- 230000002378 acidificating effect Effects 0.000 abstract description 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 238000011112 process operation Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 239000007787 solid Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 26
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 25
- 239000000047 product Substances 0.000 description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 238000000967 suction filtration Methods 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 208000025721 COVID-19 Diseases 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- 208000001528 Coronaviridae Infections Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 2
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 2
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 2
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 2
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 2
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 2
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical class C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical class C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- KRTGJZMJJVEKRX-UHFFFAOYSA-N 2-phenylethan-1-yl Chemical group [CH2]CC1=CC=CC=C1 KRTGJZMJJVEKRX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 1
- 229930182831 D-valine Natural products 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000004305 biphenyl Chemical class 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical group OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- LSACYLWPPQLVSM-UHFFFAOYSA-N isobutyric acid anhydride Chemical compound CC(C)C(=O)OC(=O)C(C)C LSACYLWPPQLVSM-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000005039 triarylmethyl group Chemical group 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
技术领域technical field
本发明涉及有机合成技术领域,具体涉及一种核苷类化合物的制备方法。The invention relates to the technical field of organic synthesis, in particular to a preparation method of a nucleoside compound.
背景技术Background technique
瑞德西韦(Remdesivir)属于核苷类似物,是RNA依赖的RNA聚合酶(RdRp) 抑制剂,可以通过抑制病毒核酸合成抗病毒,是目前唯一上市的用于SARS-CoV-2 感染的药物。虽然瑞德西韦已获FDA批准用于新型冠状病毒感染(SARS-CoV-2 的治疗,但其疗效仍存在疑问。由于瑞德西韦的分子合成步骤长、价格昂贵且需要强制性静脉注射,其应用和可及性受到限制。Remdesivir, a nucleoside analog, is an RNA-dependent RNA polymerase (RdRp) inhibitor, which can inhibit the synthesis of viral nucleic acid and is antiviral. It is the only drug currently on the market for SARS-CoV-2 infection . Although remdesivir has been approved by the FDA for the treatment of new coronavirus infection (SARS-CoV-2), its efficacy remains in doubt. Due to the long molecular synthesis steps of remdesivir, expensive and requiring mandatory intravenous injection , its application and accessibility are limited.
因此,快速开发一种有效的抗新冠病毒药物或者疫苗,是目前药物研发的重要任务。Therefore, the rapid development of an effective anti-coronavirus drug or vaccine is an important task of current drug research and development.
本研究团队发现瑞德西韦的代谢产物GS-441524,在小鼠模型中有效抑制 SARS-CoV-2感染。GS-441524与瑞德西韦相比,结构简单、合成步骤短,成本低廉,适合作为疫情应急药物快速大量生产。瑞德西韦的临床药代动力学研究表明代谢产物GS-441524在人体中半衰期约为27h,具有良好的药代性质。 GS-441524抗COVID-19及其他冠状病毒感染的安全有效性,凸显了开展治疗 COVID-19临床试验研究的必要性。为了克服GS-441524极性较大,膜渗透性差等问题,课题组开发了候选药物GS-441524的酯化衍生物作为口服抗新冠药物,具有较好的口服生物利用度,该研究成功已披露在中国专利申请 CN2020116139433,名称为一种用于治疗冠状病毒感染的核苷类化合物及其前药中,因此,对GS-441524的酯化衍生物的合成工艺研究具有重要意义,以提供药代等试验的原料药。The research team found that GS-441524, the metabolite of Remdesivir, effectively inhibited SARS-CoV-2 infection in a mouse model. Compared with remdesivir, GS-441524 has a simple structure, short synthesis steps and low cost, and is suitable for rapid mass production as an emergency drug for epidemics. Clinical pharmacokinetic studies of Remdesivir show that the half-life of metabolite GS-441524 in humans is about 27h, with good pharmacokinetic properties. The safety and efficacy of GS-441524 against COVID-19 and other coronavirus infections underscores the need for clinical trials in the treatment of COVID-19. In order to overcome the problems of high polarity and poor membrane permeability of GS-441524, the research group developed an esterified derivative of the candidate drug GS-441524 as an oral anti-COVID-19 drug, which has good oral bioavailability. The success of this study has been disclosed. In Chinese patent application CN2020116139433, the title is a nucleoside compound and its prodrug for treating coronavirus infection, therefore, it is of great significance to study the synthesis process of esterified derivatives of GS-441524 to provide pharmacokinetics and other test raw materials.
Liu等人(Tetrahedron,71(9),1409-1412;2015)在制备5’-位氨基酸酯前药时,首先将核苷类药物与三芳基甲基化试剂选择性地进行5’-位伯醇成醚保护,然后与烯丙氧羰基化试剂将剩下的羟基和氨基等活性官能团进行保护,继而在酸性条件下选择性脱去三芳基甲基保护基,然后与羧酸缩合,最后醋酸钯脱去烯丙氧羰基保护基,实现了区域选择性地在5’-位酯化。但是这条路线较长,上保护脱保护步骤多,原子经济性不高。且有些反应如脱烯丙氧羰基的过程中需要-50℃的低温条件,设备要求高,不利于工业化生产。Liu et al. (Tetrahedron, 71(9), 1409-1412; 2015) prepared 5'-position amino acid ester prodrugs by first selectively conducting 5'-position nucleoside drugs with triaryl methylation reagents The primary alcohol is protected into ether, and then the remaining active functional groups such as hydroxyl and amino groups are protected with allyloxycarbonylation reagent, and then the triarylmethyl protecting group is selectively removed under acidic conditions, and then condensed with carboxylic acid, and finally Palladium acetate removes the allyloxycarbonyl protecting group to achieve regioselective esterification at the 5'-position. However, this route is long, with many upper protection and deprotection steps, and the atom economy is not high. And some reactions, such as the process of deallyloxycarbonylation, require a low temperature condition of -50 ° C, and the equipment requirements are high, which is not conducive to industrial production.
Scheme 1.Liu等报道的核苷类化合物5′-位区域选择性酯化方法Scheme 1.Regioselective esterification method at the 5'-position of nucleosides reported by Liu et al.
何忠贵等人(Molecular Pharmaceutics,2009,6(1),315~325)采用氯甲酸苄酯(Cbz-Cl)选择性保护阿糖胞苷4-位氨基,然后直接与氨基酸进行缩合,最后Pd 催化氢化脱保护得到5’-位酯化产物。但是这条路线没有保护核糖上的羟基,因而导致反应复杂,还发生了2’位取代产物和3’位取代产物,最终导致目标产物收率较低,也不适用于工业化生产。He Zhonggui et al. (Molecular Pharmaceutics, 2009, 6(1), 315-325) used benzyl chloroformate (Cbz-Cl) to selectively protect the 4-amino group of cytarabine, and then directly condensed with amino acids, and finally Pd catalyzed Hydrogenation deprotection yields the 5'-esterified product. However, this route does not protect the hydroxyl group on the ribose, which leads to a complicated reaction, and 2'- and 3'-substituted products also occur, resulting in a low yield of the target product, which is not suitable for industrial production.
综合已经报道的代表性的核苷类化合物5’-位羟基酯化的合成路线,都存在一定的缺点。因此,设计出一条适合工业化生产的路线十分必要。Synthesizing the reported synthetic routes for the 5'-hydroxyl esterification of nucleoside compounds, all have certain shortcomings. Therefore, it is necessary to design a route suitable for industrial production.
发明内容SUMMARY OF THE INVENTION
本发明目的是提供一种核苷类化合物的反应路线,该工艺技术路线短、环境污染小、工艺操作简单。The purpose of the present invention is to provide a reaction route for nucleoside compounds, which has the advantages of short technological route, little environmental pollution and simple technological operation.
为此,本发明提供的技术方案如下:For this reason, the technical scheme provided by the invention is as follows:
一种核苷类化合物(式I)的合成方法,A kind of synthetic method of nucleoside compound (formula I),
其中,R1为-C(=O)CHR2R3;R2选自C1-C10烷基、芳烷基;R3选自H、氨基、 C1-C10烷基;或R2R3形成C3-C10碳环基;Wherein, R 1 is -C(=O)CHR 2 R 3 ; R 2 is selected from C 1 -C 10 alkyl, aralkyl; R 3 is selected from H, amino, C 1 -C 10 alkyl; or R 2 R 3 forms a C 3 -C 10 carbocyclyl;
包括如下步骤:It includes the following steps:
1)化合物(GS-441524)在2,2-二甲氧基丙烷与脱水剂存在下选择性保护羟基获得式II所示化合物;1) Compound (GS-441524) selectively protects the hydroxyl group in the presence of 2,2-dimethoxypropane and a dehydrating agent to obtain the compound shown in formula II;
2)式II所示化合物与有机羧酸选择性地与5’-位羟基缩合成酯(式III);2) The compound shown in formula II and organic carboxylic acid are selectively condensed with 5'-hydroxyl group to form ester (formula III);
3)式III所示化合物脱去缩酮保护获得核苷类化合物(式I)。3) The compound represented by formula III is removed from the ketal protection to obtain a nucleoside compound (formula I).
在一些实施例中,步骤1所述的脱水剂为对甲苯磺酸、甲磺酸或浓硫酸。在一些实施例中,所述脱水剂为浓硫酸,且所述选择性保护羟基是在约35摄氏度至回流条件下进行,优选在约40摄氏度至约50摄氏度下进行,更优选45摄氏度下进行。在一些实施例中,步骤1所述的脱水剂为对甲苯磺酸、甲磺酸,所述选择性保护羟基是在回流甲苯中进行。In some embodiments, the dehydrating agent described in step 1 is p-toluenesulfonic acid, methanesulfonic acid or concentrated sulfuric acid. In some embodiments, the dehydrating agent is concentrated sulfuric acid, and the selective protection of hydroxyl groups is performed at about 35 degrees Celsius to reflux conditions, preferably about 40 degrees Celsius to about 50 degrees Celsius, and more preferably 45 degrees Celsius. . In some embodiments, the dehydrating agent described in step 1 is p-toluenesulfonic acid and methanesulfonic acid, and the selective protection of hydroxyl groups is carried out in refluxing toluene.
在一些实施例中,步骤1后处理先用少量乙酸乙酯溶解,再将溶液倒入到不良溶剂中搅拌,不良溶剂包括石油醚、正己烷、正庚烷等。In some embodiments, the post-treatment in step 1 is first dissolved with a small amount of ethyl acetate, and then the solution is poured into a poor solvent and stirred, and the poor solvent includes petroleum ether, n-hexane, n-heptane, and the like.
在一些实施例中,步骤2所述有机酸为R为HO-C(=O)CHR2R3;R2选自C1-C10烷基、芳烷基;R3选自H、氨基、C1-C10烷基;或R2R3形成C3-C10碳环基。In some embodiments, the organic acid in step 2 is that R is HO-C(=O)CHR 2 R 3 ; R 2 is selected from C 1 -C 10 alkyl, aralkyl; R 3 is selected from H, amino , C 1 -C 10 alkyl; or R 2 R 3 forms a C 3 -C 10 carbocyclyl.
在一些实施例中,步骤2所述缩合反应在DCC/DMAP或EDCI/HOBt存在下进行,优选DCC/DMAP体系进行反应。In some embodiments, the condensation reaction in step 2 is carried out in the presence of DCC/DMAP or EDCI/HOBt, preferably the reaction is carried out in a DCC/DMAP system.
在一些实施例中,步骤2所述缩合反应控制温度在5-10℃下,将DCC滴加到反应体系中。In some embodiments, the condensation reaction in step 2 controls the temperature at 5-10° C., and DCC is added dropwise to the reaction system.
在一些实施例中,所述R2选自C1-C8烷基、芳甲基;R3选自H、氨基、C1-C6烷基;或R2R3形成C3-C7碳环基。In some embodiments, the R 2 is selected from C 1 -C 8 alkyl, arylmethyl; R 3 is selected from H, amino, C 1 -C 6 alkyl; or R 2 R 3 forms C 3 -C 7 carbocyclyl.
在一些实施例中,所述R2选自C1-C8烷基,R3选自H。In some embodiments, the R 2 is selected from C 1 -C 8 alkyl, and R 3 is selected from H.
在一些实施例中,所述C1-C8烷基为甲基、乙基、丙基、异丙基、丁基或异丁基等。In some embodiments, the C 1 -C 8 alkyl group is methyl, ethyl, propyl, isopropyl, butyl, or isobutyl, and the like.
在一些实施例中,如权利要求1所述的合成方法,步骤3所述脱保护所用的酸包括浓盐酸、6N盐酸、3N盐酸、甲酸、98%甲酸、80%甲酸、乙酸、90%乙酸、 TFA、95%TFA、PPTS、甲磺酸、对甲苯磺酸一水合物等,优选6N盐酸。In some embodiments, the synthetic method of claim 1, the acid used for the deprotection in step 3 comprises concentrated hydrochloric acid, 6N hydrochloric acid, 3N hydrochloric acid, formic acid, 98% formic acid, 80% formic acid, acetic acid, 90% acetic acid , TFA, 95% TFA, PPTS, methanesulfonic acid, p-toluenesulfonic acid monohydrate, etc., preferably 6N hydrochloric acid.
在一些实施例中,如权利要求1所述的合成方法,步骤3在-10摄氏度到室温条件下反应。In some embodiments, the synthetic method of claim 1, step 3 is reacted at -10 degrees Celsius to room temperature.
在一些实施例中,所述核苷类化合物(式I)为以下化合物:In some embodiments, the nucleoside compound (Formula I) is the following compound:
为了方便说明,以异丁酸酯前药的合成为例,中间体和产物的结构编号如下:For the convenience of explanation, taking the synthesis of isobutyrate prodrugs as an example, the structure numbers of intermediates and products are as follows:
在一些实施例中,步骤1)反应3-8h后,后处理用碳酸氢钠调pH7-8,减压蒸馏回收丙酮,向剩余物中加入乙酸乙酯,乙酸乙酯水洗,干燥,抽滤蒸干。In some embodiments, step 1) after the reaction for 3-8 hours, the post-treatment is adjusted to pH 7-8 with sodium bicarbonate, acetone is recovered by distillation under reduced pressure, ethyl acetate is added to the residue, washed with ethyl acetate, dried, and suction filtered Evaporate dry.
在一些实施例中,上述的一种核苷类化合物的合成方法,步骤1)反应3-8h 后,还包括蒸除去乙酸乙酯后的剩余物缓慢加入到产物的不良溶剂中,快速搅拌,缓慢析出固体,抽滤,用不良溶剂淋洗滤饼,干燥得到白色固体中间体II。In some embodiments, the above-mentioned method for synthesizing a nucleoside compound, step 1) after the reaction for 3-8 hours, the residue after the ethyl acetate is evaporated and slowly added to the poor solvent of the product, and rapidly stirred, The solid was slowly precipitated, filtered with suction, the filter cake was rinsed with a poor solvent, and dried to obtain intermediate II as a white solid.
在一些实施例中,所述的合成方法,步骤2)HPLC监测反应原料消耗完全后,于冰浴下加入酸将未反应完全的DCC转化为DCU,搅拌10分钟后直接抽滤,滤液分层,分出有机层,有机层分别用酸洗、碱洗、水洗、饱和氯化钠洗,无水硫酸钠干燥,抽滤蒸干产物直接用于下一步反应;所用的酸为20%柠檬酸、氯化铵、1N盐酸中的一种,所用的碱为饱和碳酸氢钠溶液、饱和碳酸钠溶液、氨水中的一种或几种。进一步的对反应过程各物质含量进行检测,来确定具体的反应时间,结果如下:In some embodiments, in the described synthetic method, step 2) HPLC monitoring reaction raw material consumption is complete, adding acid under ice bath to convert unreacted DCC into DCU, stirring for 10 minutes and then directly suction filtration, and the filtrate is layered , separate the organic layer, the organic layer was washed with acid, alkali, water, saturated sodium chloride, dried over anhydrous sodium sulfate, and the product was directly used for the next step by suction filtration and evaporation; the acid used was 20% citric acid , one of ammonium chloride and 1N hydrochloric acid, and the base used is one or more of saturated sodium bicarbonate solution, saturated sodium carbonate solution and ammonia water. The content of each substance in the reaction process is further detected to determine the specific reaction time, and the results are as follows:
从表中结果可知,在反应3.5小时后,原料基本消耗完毕,且有少量双酰化副产物IMP01开始生成。因此,反应时间优选3.5~4h。As can be seen from the results in the table, after 3.5 hours of reaction, the raw materials are basically consumed, and a small amount of bisacylated by-product IMP01 begins to be generated. Therefore, the reaction time is preferably 3.5 to 4 hours.
在一些实施例中,步骤3)中所述脱去缩酮保护在酸存在下进行,所述的酸为浓盐酸、6N盐酸、3N盐酸、甲酸、98%甲酸、80%甲酸、乙酸、90%乙酸、TFA、 95%TFA、PPTS、甲磺酸、对甲苯磺酸一水合物,综合考虑物料价格和后处理因素,优选6N盐酸,该反应选用的溶剂选自1-6个碳的醇类溶剂、醚性溶剂,所述的醇类溶剂选自甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇、叔丁醇,或这些溶剂的不同组合;所述的醚性溶剂选自乙醚、甲基叔丁基醚、二异丙基醚、四氢呋喃、2-甲基四氢呋喃、1,2-二甲氧基乙烷、1,4-二氧六环或这些溶剂的不同组合,优选四氢呋喃。反应温度为-20~25℃,优选0℃。In some embodiments, the deketal protection described in step 3) is carried out in the presence of an acid, and the acid is concentrated hydrochloric acid, 6N hydrochloric acid, 3N hydrochloric acid, formic acid, 98% formic acid, 80% formic acid, acetic acid, 90% formic acid % acetic acid, TFA, 95% TFA, PPTS, methanesulfonic acid, p-toluenesulfonic acid monohydrate, comprehensively considering material price and post-processing factors, preferably 6N hydrochloric acid, the solvent selected for this reaction is selected from 1-6 carbon alcohols Solvents, ether solvents, the alcohol solvents are selected from methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, or different combinations of these solvents; the ether The organic solvent is selected from diethyl ether, methyl tert-butyl ether, diisopropyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane or any of these solvents. Different combinations, preferably tetrahydrofuran. The reaction temperature is -20 to 25°C, preferably 0°C.
在一些实施例中,所述的合成方法,其中步骤3)HPLC监测反应完全后,用碳酸氢钠调pH7-8,加入乙酸乙酯萃取,乙酸乙酯层分别用水、饱和食盐水洗,硫酸镁干燥,抽滤蒸干回收溶剂,得粗品。进一步的对反应过程各物质含量进行检测,来确定具体的反应时间,结果如下:In some embodiments, in the synthetic method described in step 3), after the HPLC monitoring reaction is complete, the pH is adjusted to 7-8 with sodium bicarbonate, ethyl acetate is added for extraction, the ethyl acetate layer is washed with water and saturated brine, respectively, and magnesium sulfate Dry, filter and evaporate to dryness to recover the solvent to obtain crude product. The content of each substance in the reaction process is further detected to determine the specific reaction time, and the results are as follows:
从表中可以看出,6N HCl脱保护的最佳反应时间为9h左右。It can be seen from the table that the optimal reaction time for 6N HCl deprotection is about 9h.
在一些实施例中,所述的合成方法,其中步骤3)采用柱层析的方法,以二氯甲烷、甲醇为洗脱剂,可以获得较纯的式(I)所示化合物,其HPLC纯度为90%以上,优选95%以上,更优选97%以上。In some embodiments, the synthetic method, wherein step 3) adopts the method of column chromatography, using dichloromethane and methanol as eluents, can obtain a relatively pure compound represented by formula (I), and its HPLC purity It is 90% or more, preferably 95% or more, and more preferably 97% or more.
本发明的是提供一种核苷类化合物的反应路线,该工艺技术路线短、环境污染小、工艺操作简单。The present invention provides a reaction route of nucleoside compounds, which has short technical route, little environmental pollution and simple technological operation.
为了实现本发明目的,本发明首先考虑采用化合物GS-441524作为起始物料,经过本发明的技术方案只需要3步反应就能得到终产品,In order to achieve the purpose of the present invention, the present invention first considers using the compound GS-441524 as the starting material, and through the technical solution of the present invention, the final product can be obtained with only three steps of reaction,
(GS-441524),而选择GS-441524做为起始物料需要解决如下技术问题:本领域技术人员知晓化合物GS-441524具有1,2,3三个羟基活性基团和4氨基活性基团,第一步需要选择合适的反应条件选择性的保护2,3羟基,经过不断尝试,最终发现在2,2-二甲氧基丙烷与浓硫酸结合可以高度的选择保护 2,3羟基;要获得化合物GS-441524的酯化衍生物,需要式II所示化合物与有机羧酸选择性地在5’-位羟基缩合成酯(式III);而氨基基本不发生缩合反应 (GS-441524), and selecting GS-441524 as starting material needs to solve the following technical problems: those skilled in the art know that compound GS-441524 has 1, 2, 3 three hydroxyl active groups and 4 amino active groups, The first step is to select suitable reaction conditions to selectively protect the 2,3 hydroxyl group. After continuous attempts, it was finally found that the combination of 2,2-dimethoxypropane and concentrated sulfuric acid can highly selectively protect the 2,3 hydroxyl group; to obtain The esterified derivative of compound GS-441524 requires the compound represented by formula II and organic carboxylic acid to selectively condense into ester (formula III) at the 5'-position hydroxyl group; while the amino group basically does not undergo condensation reaction
经过不断尝试,最终发现以DCC/DMAP作为缩合剂可以选择性在5’-位羟基缩合成酯,而当用EDCI/HOBt或酸酐/三乙胺体系进行缩合时,容易生成相当比例的双酰化副产物。After continuous attempts, it was finally found that DCC/DMAP can be used as a condensing agent to selectively condense a hydroxyl group at the 5'-position into an ester, and when EDCI/HOBt or anhydride/triethylamine system is used for condensation, it is easy to generate a considerable proportion of bisacyl. by-products.
总之,与现有技术相比,本发明提供的技术方案具有如下优点:In a word, compared with the prior art, the technical scheme provided by the present invention has the following advantages:
1)本发明提供的技术方案只需要通过3步反应就能得到终产品,反应路线短,没有用到繁琐的保护基,原子经济性高。在缩合反应过程中,通过低温缓慢滴加缩合剂的方法,控制双酰化副产物的产生。1) The technical solution provided by the present invention can obtain the final product only through 3-step reaction, the reaction route is short, no complicated protective group is used, and the atom economy is high. During the condensation reaction, the generation of bisacylated by-products is controlled by slowly adding a condensing agent dropwise at a low temperature.
2)本发明提供的技术方案采用的路线,没有用到污染严重的试剂或溶剂,属于环境友好型工艺。2) The route adopted by the technical solution provided by the present invention does not use seriously polluted reagents or solvents, and belongs to an environment-friendly process.
3)本发明提供的技术方案采用的路线主要在0-50℃之间进行,设备成本低,能耗较少。3) The route adopted by the technical solution provided by the present invention is mainly carried out between 0-50° C., the equipment cost is low, and the energy consumption is low.
术语说明:Terminology Description:
本发明中“室温”指的是环境温度,温度由大约10℃到大约40℃。在一些实施例中,“室温”指的是温度由大约20℃到大约30℃;在另一些实施例中,“室温”指的是温度由大约25℃到大约30℃;在又一些实施例中,“室温”指的是10℃、 15℃、20℃、25℃、30℃、35℃、40℃等。In the present invention, "room temperature" refers to ambient temperature, which is from about 10°C to about 40°C. In some embodiments, "room temperature" refers to a temperature from about 20°C to about 30°C; in other embodiments, "room temperature" refers to a temperature from about 25°C to about 30°C; in still other embodiments Among them, "room temperature" refers to 10°C, 15°C, 20°C, 25°C, 30°C, 35°C, 40°C, and the like.
“烷基”是包含伯碳原子、仲碳原子、叔碳原子或环碳原子的烃。例如,烷基可以具有1至10个碳原子(即,C1-C10烷基)、1至8个碳原子(即,C1-C8烷基) 或1至6个碳原子(即,C1-C6烷基)。合适的烷基的实例包括但不限于,甲基(Me、 -CH3)、乙基(Et、-CH2CH3)、1-丙基(i-Pr、i-丙基、-CH2CH2CH3)、2-丙基(i-Pr、 i-丙基、-CH(CH3)2)、1-丁基(n-Bu、n-丁基、-CH2CH2CH2CH3)、2-甲基-1-丙基(i-Bu、 i-丁基、-CH2CH(CH3)2)、2-丁基(s-Bu、s-丁基、-CH(CH3)CH2CH3)、2-甲基-2- 丙基(t-Bu、t-丁基、-C(CH3)3)、1-戊基(n-戊基、-CH2CH2CH2CH2CH3)、2-戊基 (-CH(CH3)CH2CH2CH3)、3-戊基(-CH(CH2CH3)2)、2-甲基-2-丁基(-C(CH3)2CH2CH3)、3-甲-2-丁基(-CH(CH3)CH(CH3)2)、3-甲基-1-丁基(-CH2CH2CH(CH3)2)、2-甲基-1- 丁基(-CH2CH(CH3)CH2CH3)、1-己基(-CH2CH2CH2CH2CH2CH3)、2-己基 (-CH(CH3)CH2CH2CH2CH3)、3-己基(-CH(CH2CH3)(CH2CH2CH3))、2-甲基-2-戊基 (-C(CH3)2CH2CH2CH3)、3-甲基-2-戊基(-CH(CH3)CH(CH3)CH2CH3)、4-甲基-2-戊基(-CH(CH3)CH2CH(CH3)2)、3-甲基-3-戊基(-C(CH3)(CH2CH3)2)、2-甲基-3-戊基 (-CH(CH2CH3)CH(CH3)2)、2,3-二甲基-2-丁基(-C(CH3)2CH(CH3)2)、3,3-二甲基-2- 丁基(-CH(CH3)C(CH3)3和辛基(-(CH2)7CH3)。"Alkyl" is a hydrocarbon containing primary, secondary, tertiary, or ring carbon atoms. For example, an alkyl group can have 1 to 10 carbon atoms (ie, a C1 - C10 alkyl group), 1 to 8 carbon atoms (ie, a C1 -C8 alkyl group), or 1 to 6 carbon atoms (ie, a C1-C8 alkyl group). , C 1 -C 6 alkyl). Examples of suitable alkyl groups include, but are not limited to, methyl (Me, -CH3 ), ethyl (Et, -CH2CH3), 1 -propyl (i-Pr, i-propyl, -CH2 ) CH 2 CH 3 ), 2-propyl (i-Pr, i-propyl, -CH(CH 3 ) 2 ), 1-butyl (n-Bu, n-butyl, -CH 2 CH 2 CH 2 ) CH 3 ), 2-methyl-1-propyl (i-Bu, i-butyl, -CH 2 CH(CH 3 ) 2 ), 2-butyl (s-Bu, s-butyl, -CH (CH 3 )CH 2 CH 3 ), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH 3 ) 3 ), 1-pentyl (n-pentyl, -CH 2CH2CH2CH2CH3), 2 -pentyl (-CH( CH3 ) CH2CH2CH3 ) , 3 - pentyl (-CH( CH2CH3 ) 2 ) , 2 -methyl -2-butyl (-C(CH 3 ) 2 CH 2 CH 3 ), 3-methyl-2-butyl (-CH(CH 3 )CH(CH 3 ) 2 ), 3-methyl-1-butane (-CH 2 CH 2 CH(CH 3 ) 2 ), 2-methyl-1-butyl (-CH 2 CH(CH 3 )CH 2 CH 3 ), 1-hexyl (-CH 2 CH 2 CH 2 CH2CH2CH3 ), 2 -hexyl (-CH( CH3 ) CH2CH2CH2CH3 ) , 3 - hexyl (-CH( CH2CH3 ) ( CH2CH2CH3 ) ) , 2-Methyl-2-pentyl (-C(CH 3 ) 2 CH 2 CH 2 CH 3 ), 3-methyl-2-pentyl (-CH(CH 3 )CH(CH 3 )CH 2 CH 3 ), 4-methyl-2-pentyl (-CH(CH 3 )CH 2 CH(CH 3 ) 2 ), 3-methyl-3-pentyl (-C(CH 3 )(CH 2 CH 3 ) 2 ), 2-methyl-3-pentyl (-CH(CH 2 CH 3 )CH(CH 3 ) 2 ), 2,3-dimethyl-2-butyl (-C(CH 3 ) 2 CH ( CH3 ) 2 ), 3,3-dimethyl-2-butyl (-CH( CH3 )C( CH3 ) 3 , and octyl ( - ( CH2 ) 7CH3 ).
芳基”意指通过从母体芳环系统的单个碳原子除去一个氢原子衍生的芳族烃基。例如,芳基可以具有6至20个碳原子、6至14个碳原子或6至10个碳原子。典型的芳基包括但不限于,从苯(例如,苯基)、取代的苯、萘、蒽、联苯等衍生的基团以及类似基团。"Aryl" means an aromatic hydrocarbon group derived by removing one hydrogen atom from a single carbon atom of the parent aromatic ring system. For example, an aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 10 carbon atoms Atom. Typical aryl groups include, but are not limited to, groups derived from benzene (eg, phenyl), substituted benzene, naphthalene, anthracene, biphenyl, and the like, and the like.
“芳基烷基”是指其中键合至碳原子(通常是末端或sp3碳原子)的氢原子中的一个被芳基代替的无环烷基。典型的芳基烷基包括但不限于,苄基、2-苯基乙-1- 基、萘基甲基、2-萘基乙-1-基、萘并苄基、2-萘并苯基乙-1-基以及类似物。芳基烷基可以包括7至20个碳原子,例如,烷基部分是I至6个碳原子,且芳基部分是6至14个碳原子。"Arylalkyl" refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom (usually a terminal or sp3 carbon atom) is replaced by an aryl group. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, naphthobenzyl, 2-naphthophenyl Ethan-1-yl and the like. Arylalkyl groups can include 7 to 20 carbon atoms, eg, the alkyl moiety is 1 to 6 carbon atoms, and the aryl moiety is 6 to 14 carbon atoms.
具体实施方式Detailed ways
下面结合具体实施方式,对本发明的权利要求做进一步的详细说明。The claims of the present invention will be further described in detail below in conjunction with the specific embodiments.
实施例1式(Ia)所示化合物的制备方法The preparation method of compound represented by embodiment 1 formula (Ia)
1)在500mL反应器中,安装好搅拌器、温度计、恒压滴液漏斗,加入 GS-441524(10g,0.03mol),加入硫酸镁干燥的丙酮(300mL),再加入2,2-二甲氧基丙烷(17g,0.16mol),于室温下向体系中滴加浓硫酸(2.4mL,0.04mol),5 min后滴加完毕,固体开始溶解,升温至45℃继续反应4h,HPLC监测反应完全(OD-3柱,流动相:正己烷/异丙醇=80:20,流速:0.8mL/min,进样量1μL),停止反应,冰浴冷却后,向反应液中加入NaHCO3固体(10g),水(30mL),继续用碳酸氢钠调pH至7-8、减压蒸馏去除溶剂,剩余物用乙酸乙酯(300mL)稀释,乙酸乙酯层分别用水(80mL),饱和食盐水(80mL)洗,无水硫酸钠干燥。抽滤,滤液减压蒸馏至剩余100mL左右溶剂,将剩余物缓慢倒入冰浴冷却的石油醚中,并剧烈搅拌,洗出大量白色固体,抽滤得到10.5g白色固体,收率为 91%。1) In a 500mL reactor, install a stirrer, a thermometer, and a constant pressure dropping funnel, add GS-441524 (10g, 0.03mol), add acetone (300mL) dried over magnesium sulfate, and then add 2,2-dimethylformaldehyde Oxypropane (17 g, 0.16 mol) was added dropwise to the system at room temperature with concentrated sulfuric acid (2.4 mL, 0.04 mol), the dropwise addition was completed after 5 min, the solid began to dissolve, the temperature was raised to 45 °C and the reaction was continued for 4 h, and the reaction was monitored by HPLC Complete (OD-3 column, mobile phase: n-hexane/isopropanol = 80:20, flow rate: 0.8 mL/min, injection volume 1 μL), stop the reaction, after cooling in ice bath, add NaHCO 3 solid to the reaction solution (10g), water (30mL), the pH was adjusted to 7-8 with sodium bicarbonate, the solvent was distilled off under reduced pressure, the residue was diluted with ethyl acetate (300mL), the ethyl acetate layer was respectively water (80mL), saturated common salt Washed with water (80 mL) and dried over anhydrous sodium sulfate. Suction filtration, the filtrate was distilled under reduced pressure to about 100 mL of solvent remaining, the residue was slowly poured into ice-cooled petroleum ether, and vigorously stirred to wash out a large amount of white solids, and suction filtration to obtain 10.5 g of white solids with a yield of 91% .
2)在500mL反应器中,安装好搅拌器、温度计、恒压滴液漏斗,分别加入上一步缩酮保护产物(10g,0.03mol),异丁酸(3.2g/0.036mol),DMAP(1.8g, 0.015mol),纯化的DCM150mL,将反应瓶至于5-10℃冷井中搅拌,向滴液漏斗中加入DCC(8g,0.04mol)的DCM溶液(50mL)。缓慢滴加DCC溶液,控制温度在10℃左右,1h后滴加完毕,继续保温反应5h后,HPLC检测反应完全,基本没有双酰化产物产生,于5-10℃下,向反应体系中加入20%柠檬酸溶液(50 mL),搅拌10min后,加入DCM(100mL)稀释,静止分层。分出有机层,有机层分别用20%柠檬酸(100mL)洗,饱和碳酸钠(80mL)洗,水(80mL)洗,饱和食盐水(80mL)洗,无水硫酸钠干燥。抽滤蒸干得到13.1g白色固体,收率为109% (含有部分副产物二环己基脲DCU),产品用100mL DCM溶解后,置于-20℃冰箱冷却,过滤去除不溶物,滤液蒸干得到10.8g油状物,收率为90%。1H NMR (400MHz,CDCl3)δ(ppm):7.99(s,1H),6.99(d,J=4.6Hz,1H),6.62(d,J=4.6Hz, 1H),5.72(br,2H),5.49(d,J=6.8Hz,1H),4.93-4.90(dd,J=6.8Hz,4.3Hz,1H),4.61-4.58(q,J=4.4Hz,1H),4.44-4.26(m,2H),2.61-2.50(m,1H),1.77(s,3H),1.42 (s,3H),1.17-1.14(q,J=3.8Hz,6H).13C NMR(100MHz,CDCl3)δ(ppm):176.7, 155.2,147.3,123.5,117.2,116.7,115.6,112.6,100.0,83.8,83.0,82.0,81.4,63.1, 33.8,26.4,25.6,18.9.2) In a 500mL reactor, install a stirrer, a thermometer, and a constant pressure dropping funnel, and add the ketal protection product (10g, 0.03mol) of the previous step, isobutyric acid (3.2g/0.036mol), DMAP (1.8 g, 0.015 mol), purified DCM 150 mL, the reaction flask was stirred in a cold well at 5-10 °C, and a solution of DCC (8 g, 0.04 mol) in DCM (50 mL) was added to the dropping funnel. Slowly add the DCC solution dropwise, control the temperature at about 10 °C, and complete the dropwise addition after 1 hour. After continuing the incubation reaction for 5 hours, HPLC detects that the reaction is complete, and basically no bisacylated product is produced. Add to the reaction system at 5-10 °C. 20% citric acid solution (50 mL) was stirred for 10 min, diluted with DCM (100 mL), and the layers were statically separated. The organic layer was separated, washed with 20% citric acid (100 mL), saturated sodium carbonate (80 mL), water (80 mL), saturated brine (80 mL), and dried over anhydrous sodium sulfate. Suction filtration and evaporated to dryness to obtain 13.1 g of white solid with a yield of 109% (containing part of the by-product dicyclohexylurea DCU), the product was dissolved in 100 mL of DCM, cooled in a -20°C refrigerator, filtered to remove insolubles, and the filtrate was evaporated to dryness 10.8 g of oil was obtained in 90% yield. 1 H NMR (400MHz, CDCl 3 )δ(ppm): 7.99(s, 1H), 6.99(d, J=4.6Hz, 1H), 6.62(d, J=4.6Hz, 1H), 5.72(br, 2H) ),5.49(d,J=6.8Hz,1H),4.93-4.90(dd,J=6.8Hz,4.3Hz,1H),4.61-4.58(q,J=4.4Hz,1H),4.44-4.26(m , 2H), 2.61-2.50 (m, 1H), 1.77 (s, 3H), 1.42 (s, 3H), 1.17-1.14 (q, J=3.8Hz, 6H). 13 C NMR (100MHz, CDCl 3 ) δ(ppm): 176.7, 155.2, 147.3, 123.5, 117.2, 116.7, 115.6, 112.6, 100.0, 83.8, 83.0, 82.0, 81.4, 63.1, 33.8, 26.4, 25.6, 18.9.
3)在250mL反应器中,安装好搅拌器、温度计、恒压滴液漏斗,加入步骤2缩合产物(10.8g,0.027mol),用THF(90mL)溶解,将反应瓶置于0℃冷井中搅拌,缓慢滴加6N HCl(90mL,0.54mol),加毕后保温反应7h,HPLC监测原料消耗完全,停止反应,用NaHCO3固体调pH7~8,减压蒸馏去除THF,有固体析出,用乙酸乙酯萃取(150mL×2),合并乙酸乙酯层,分别水(100mL)洗,饱和食盐水(100mL)洗,硫酸镁干燥。抽滤蒸干得到8g粗品,柱层析(1.2倍硅胶拌样,5倍硅胶装柱子,洗脱剂:二氯甲烷/甲醇=40:1),得到纯品6.5g,回收GS-4415241g,收率为66.3%,纯度:98.82%(色谱条件:柱子:OD-3,流动相:正己烷:异丙醇=80:20,流速:0.8mL/min,进样量:1μL)。1H NMR(600MHz, DMSO-d6)δ(ppm):7.93(s,1H),7.89(br,2H),6.92(d,J=4.3Hz,1H),6.81(d,J=4.3 Hz,1H),6.32(d,J=5.9Hz,1H),5.38(d,J=5.7Hz,1H),4.7(t,J=5.2Hz,1H), 4.32-4.30(m,1H),4.25-4.22(m,1H),4.19-4.16(m,1H),3.98-3.95(q,J=5.6 Hz,1H), 2.55-2.50(m,1H),1.06-1.05(dd,J=6.8Hz,1.8Hz,6H).13C NMR(150MHz, DMSO-d6)δ(ppm):176.4,156.1,148.4,124.0,117.4,117.0,110.7,101.3,81.7,79.5, 74.5,70.6,63.4,33.6,19.2,19.1.3) In a 250mL reactor, install a stirrer, a thermometer, and a constant pressure dropping funnel, add the condensation product (10.8g, 0.027mol) of step 2, dissolve it with THF (90mL), and place the reaction flask in a cold well at 0°C Stir, slowly add 6N HCl (90 mL, 0.54 mol) dropwise, keep the reaction for 7 h after the addition, monitor the consumption of raw materials by HPLC, stop the reaction, adjust the pH to 7-8 with NaHCO 3 solid, remove THF by vacuum distillation, there is solid precipitation, use Ethyl acetate was extracted (150 mL×2), the ethyl acetate layers were combined, washed with water (100 mL), saturated brine (100 mL), and dried over magnesium sulfate. Suction filtration and evaporated to dryness to obtain 8 g of crude product, which was subjected to column chromatography (1.2 times of silica gel sample, 5 times of silica gel packed into a column, eluent: dichloromethane/methanol=40:1) to obtain 6.5 g of pure product, and GS-4415241 g was recovered, The yield was 66.3%, the purity: 98.82% (chromatographic conditions: column: OD-3, mobile phase: n-hexane: isopropanol=80:20, flow rate: 0.8 mL/min, injection volume: 1 μL). 1 H NMR (600MHz, DMSO-d 6 )δ(ppm): 7.93(s, 1H), 7.89(br, 2H), 6.92(d, J=4.3Hz, 1H), 6.81(d, J=4.3 Hz) ,1H),6.32(d,J=5.9Hz,1H),5.38(d,J=5.7Hz,1H),4.7(t,J=5.2Hz,1H), 4.32-4.30(m,1H),4.25 -4.22(m, 1H), 4.19-4.16(m, 1H), 3.98-3.95(q, J=5.6 Hz, 1H), 2.55-2.50(m, 1H), 1.06-1.05(dd, J=6.8Hz , 1.8Hz, 6H). 13 C NMR (150MHz, DMSO-d 6 )δ(ppm): 176.4, 156.1, 148.4, 124.0, 117.4, 117.0, 110.7, 101.3, 81.7, 79.5, 74.5, 70.6, 63.4, 33.6 ,19.2,19.1.
实施例2式(Ia)所示化合物的制备方法Embodiment 2 The preparation method of compound represented by formula (Ia)
1)在1000mL反应器中,安装好搅拌器、温度计、恒压滴液漏斗,加入 GS-441524(30g,0.10mol),加入甲苯(600mL),再加入2,2-二甲氧基丙烷(51g, 0.48mol),于室温下向体系中加入对甲苯磺酸(0.13mol),10min后滴加完毕,升温至回流继续反应2h,HPLC监测反应完全,停止反应,冰浴冷却后,向反应液中加入NaHCO3固体(30g),水(15mL),继续用碳酸氢钠调pH至7-8,减压蒸馏去除溶剂,向剩余物中加入乙酸乙酯(500mL),水(100mL),搅拌分出有机层,有机层分别用水(100mL)、饱和食盐水(100mL)洗,无水硫酸钠干燥。抽滤,滤液减压蒸馏至剩余100mL左右溶剂,将剩余物缓慢倒入冰浴冷却的石油醚中,并剧烈搅拌,洗出大量白色固体,抽滤得到10.5g白色固体,收率为 91%。1) In a 1000mL reactor, install a stirrer, a thermometer, and a constant pressure dropping funnel, add GS-441524 (30g, 0.10mol), add toluene (600mL), and then add 2,2-dimethoxypropane ( 51g, 0.48mol), add p-toluenesulfonic acid (0.13mol) to the system at room temperature, the dropwise addition is completed after 10min, the temperature is raised to reflux and the reaction is continued for 2h. NaHCO3 solid (30g), water (15mL) were added to the liquid, the pH was adjusted to 7-8 with sodium bicarbonate, the solvent was distilled off under reduced pressure, ethyl acetate (500mL), water (100mL) were added to the residue, The organic layer was separated by stirring, and the organic layer was washed with water (100 mL) and saturated brine (100 mL), respectively, and dried over anhydrous sodium sulfate. Suction filtration, the filtrate was distilled under reduced pressure to about 100 mL of solvent remaining, the residue was slowly poured into ice-cooled petroleum ether, and vigorously stirred to wash out a large amount of white solids, and suction filtration to obtain 10.5 g of white solids with a yield of 91% .
2)在1000mL反应器中,安装好搅拌器、温度计、恒压滴液漏斗,分别加入上一步缩酮保护产物(30g,0.09mol),异丁酸(9.6g/0.108mol),DMAP(5.4g, 0.045mol),DCM 300mL,将反应瓶至于5-10℃冷井中搅拌,向滴液漏斗中加入DCC(24g,0.12mol)的DCM溶液(150mL)。缓慢滴加DCC溶液,控制温度在10℃左右,1h后滴加完毕,继续保温反应5h后,HPLC检测反应完全,于 5-10℃下,向反应体系中加入20%柠檬酸溶液(50mL),搅拌10min后,抽滤去除DCU,滤液静止分层。分出有机层,有机层分别用20%柠檬酸洗(100mL×2),饱和碳酸钠溶液洗(100mL×1),水洗(100mL×1),饱和食盐水洗(100mL×1),无水硫酸钠干燥。抽滤蒸干得到36g白色固体,收率为99.7%,无需纯化直接用于下一步反应。2) In the 1000mL reactor, install a stirrer, a thermometer, and a constant pressure dropping funnel, and add the ketal protection product (30g, 0.09mol) of the previous step, isobutyric acid (9.6g/0.108mol), DMAP (5.4 g, 0.045 mol), DCM 300 mL, the reaction flask was stirred in a cold well at 5-10 °C, and a solution of DCC (24 g, 0.12 mol) in DCM (150 mL) was added to the dropping funnel. The DCC solution was slowly added dropwise, and the temperature was controlled at about 10 °C. The dropwise addition was completed after 1 h. After the reaction was continued for 5 h, HPLC detected that the reaction was complete. At 5-10 °C, 20% citric acid solution (50 mL) was added to the reaction system. , After stirring for 10 min, DCU was removed by suction filtration, and the filtrate was statically stratified. Separate the organic layer, wash the organic layer with 20% citric acid (100mL×2), saturated sodium carbonate solution (100mL×1), water (100mL×1), saturated brine (100mL×1), anhydrous sulfuric acid Sodium dry. Suction filtration was evaporated to dryness to obtain 36 g of white solid with a yield of 99.7%, which was directly used in the next reaction without purification.
3)在1000mL反应器中,安装好搅拌器、温度计、恒压滴液漏斗,加入步骤2缩合产物(36g,0.09mol),用THF(300mL)溶解,将反应瓶置于0℃冷井中搅拌,缓慢滴加6N HCl(300mL,1.8mol),加毕后保温反应7h,HPLC监测原料消耗完全,停止反应,用NaHCO3固体调pH7~8,减压蒸馏去除THF,用乙酸乙酯萃取(300mL×2),合并乙酸乙酯层,分别水(150mL)洗,饱和食盐水(150 mL)洗,硫酸镁干燥。抽滤蒸干得到30g粗品,柱层析(1.2倍硅胶拌样,5倍硅胶装柱子,洗脱剂:二氯甲烷/甲醇=40:1),得到纯品20g,回收GS-441524 0.8g,与步骤2合并收率为61.5%,纯度:100%。3) In a 1000mL reactor, install a stirrer, a thermometer, and a constant pressure dropping funnel, add the condensation product (36g, 0.09mol) of step 2, dissolve it with THF (300mL), and place the reaction flask in a 0°C cold well and stir , 6N HCl (300mL, 1.8mol) was slowly added dropwise, and the reaction was incubated for 7h after the addition was completed. HPLC monitored that the raw materials were consumed completely, stopped the reaction, and adjusted the pH to 7-8 with NaHCO 3 solid, distilled under reduced pressure to remove THF, and extracted with ethyl acetate ( 300 mL×2), the ethyl acetate layers were combined, washed with water (150 mL), saturated brine (150 mL), and dried over magnesium sulfate. Suction filtration and evaporated to dryness to obtain 30g of crude product, column chromatography (1.2 times of silica gel mixed sample, 5 times of silica gel packed into a column, eluent: dichloromethane/methanol=40:1), 20g of pure product was obtained, and 0.8g of GS-441524 was recovered. , combined with step 2, the yield is 61.5%, and the purity: 100%.
实施例3式(Ia)所示化合物的制备方法Embodiment 3 The preparation method of compound represented by formula (Ia)
1)在1000mL反应器中,安装好搅拌器、温度计、恒压滴液漏斗,加入 GS-441524(50g,0.17mol),加入硫酸镁干燥的丙酮(800mL),再加入2,2-二甲氧基丙烷(86g,0.82mol),于室温下向体系中滴加浓硫酸(12mL,0.22mol),于 45℃下滴加,10min后滴加完毕,继续反应4h,HPLC监测反应完全,停止反应,冰浴冷却后,向反应液中加入NaHCO3固体(50g),水(50mL),继续用碳酸氢钠调pH至7-8,减压蒸馏去除溶剂,向剩余物中加入乙酸乙酯(1000mL),水(150mL),搅拌分出有机层,有机层分别用水(200mL)、饱和食盐水(200mL)洗,无水硫酸钠干燥。抽滤,滤液减压蒸馏至剩余200mL左右溶剂,将剩余物缓慢倒入冰浴冷却的石油醚中,并剧烈搅拌,洗出大量白色固体,抽滤得到52g 白色固体,收率为93%。1) In a 1000mL reactor, install a stirrer, a thermometer, and a constant pressure dropping funnel, add GS-441524 (50g, 0.17mol), add acetone (800mL) dried over magnesium sulfate, and then add 2,2-dimethylformaldehyde Oxypropane (86g, 0.82mol) was added dropwise to the system at room temperature with concentrated sulfuric acid (12mL, 0.22mol), added dropwise at 45°C, the dropwise addition was completed after 10min, the reaction was continued for 4h, and the reaction was monitored by HPLC and stopped. After the reaction was cooled in an ice bath, NaHCO solid (50 g) and water (50 mL ) were added to the reaction solution, the pH was adjusted to 7-8 with sodium bicarbonate, the solvent was distilled off under reduced pressure, and ethyl acetate was added to the residue. (1000 mL), water (150 mL), and stirring to separate the organic layer, the organic layer was washed with water (200 mL) and saturated brine (200 mL), respectively, and dried over anhydrous sodium sulfate. Suction filtration, the filtrate was distilled under reduced pressure to about 200 mL of solvent remaining, the residue was slowly poured into ice-cooled petroleum ether, and vigorously stirred to wash out a large amount of white solid, and suction filtration to obtain 52 g of white solid with a yield of 93%.
2)在1000mL反应器中,安装好搅拌器、温度计、恒压滴液漏斗,分别加入上一步缩酮保护产物(40g,0.12mol),异丁酸(12.8g,0.14mol),DMAP(7.2g, 0.06mol),DCM 600mL,将反应瓶置于5-10℃冷井中搅拌,向滴液漏斗中加入DCC(32g,0.16mol)的DCM溶液(250mL)。缓慢滴加DCC溶液,控制温度在10℃左右,1.5h后滴加完毕,继续保温反应5h后,HPLC检测反应完全,于5-10℃下,向反应体系中加入20%柠檬酸溶液(100mL)搅拌,抽滤去除DCU,滤液静止分层。分出有机层,有机层分别用20%柠檬酸洗(100mL×2),饱和碳酸钠溶液洗(200mL×1),水洗(100mL×1),饱和食盐水洗(100mL×1),无水硫酸钠干燥。抽滤蒸干得到50g白色固体,无需纯化直接用于下一步反应。2) In the 1000mL reactor, install a stirrer, a thermometer, and a constant pressure dropping funnel, and add the ketal protection product (40g, 0.12mol), isobutyric acid (12.8g, 0.14mol), DMAP (7.2 mol) of the previous step, respectively. g, 0.06 mol), DCM 600 mL, the reaction flask was placed in a 5-10 °C cold well and stirred, and a solution of DCC (32 g, 0.16 mol) in DCM (250 mL) was added to the dropping funnel. The DCC solution was slowly added dropwise, and the temperature was controlled at about 10 °C. The dropwise addition was completed after 1.5 h. After the reaction was continued for 5 h, HPLC detected that the reaction was complete. At 5-10 °C, 20% citric acid solution (100 mL) was added to the reaction system ) stirring, suction filtration to remove DCU, and the filtrate is statically layered. Separate the organic layer, wash the organic layer with 20% citric acid (100mL×2), saturated sodium carbonate solution (200mL×1), water (100mL×1), saturated brine (100mL×1), anhydrous sulfuric acid Sodium dry. Suction filtration was evaporated to dryness to obtain 50 g of white solid, which was directly used in the next reaction without purification.
3)在1000mL反应器中,安装好搅拌器、温度计、恒压滴液漏斗,加入步骤2缩合产物(36g,0.09mol),用THF(300mL)溶解,将反应瓶置于0℃冷井中搅拌,缓慢滴加6N HCl(300mL,1.8mol),加毕后保温反应7h,HPLC监测原料消耗完全,停止反应,用NaHCO3固体调pH7~8,减压蒸馏去除THF,用乙酸乙酯萃取(300mL×2),合并乙酸乙酯层,分别用水(150mL)洗,饱和食盐水 (150mL)洗,硫酸镁干燥。抽滤蒸干得到40g粗品,柱层析(1.2倍硅胶拌样,5 倍硅胶装柱子,洗脱剂:二氯甲烷/甲醇=40:1),得到纯品26g,回收GS-4415242.2g,与步骤2合并收率为60%,纯度:99.2%。3) In a 1000mL reactor, install a stirrer, a thermometer, and a constant pressure dropping funnel, add the condensation product (36g, 0.09mol) of step 2, dissolve it with THF (300mL), and place the reaction flask in a 0°C cold well and stir , 6N HCl (300mL, 1.8mol) was slowly added dropwise, and the reaction was incubated for 7h after the addition was completed. HPLC monitored that the raw materials were consumed completely, stopped the reaction, and adjusted the pH to 7-8 with NaHCO 3 solid, distilled under reduced pressure to remove THF, and extracted with ethyl acetate ( 300 mL×2), the ethyl acetate layers were combined, washed with water (150 mL) and saturated brine (150 mL), respectively, and dried over magnesium sulfate. Suction filtration and evaporated to dryness to obtain 40 g of crude product, which was subjected to column chromatography (1.2 times of silica gel sample, 5 times of silica gel packed into a column, eluent: dichloromethane/methanol=40:1) to obtain 26 g of pure product, and GS-4415242.2 g was recovered, Combined with step 2, yield was 60%, purity: 99.2%.
实施例4((2R,3S,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4二羟基四氢呋喃-2-基)乙酸甲酯的制备方法Example 4 ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3 , the preparation method of 4-dihydroxytetrahydrofuran-2-yl) methyl acetate
以乙酸取代实施例1步骤2中的异丁酸,粗品收率为98%。按照实施例1 中的其余各步骤反应制备化合物Ib,得到白色固体5.6g,纯度98.7%,三步总收率为56%。1H NMR(600MHz,CD3OD)δ(ppm):7.86(s,1H),6.89(t,J=5.0Hz, 2H),4.87(s,1H),4.43-4.41(dd,J=12Hz,2.8Hz,1H),4.37-4.34(m,1H),4.30-4.27 (m,1H),4.13(t,J=5.7Hz,1H),2.03(s,3H).13C NMR(150MHz,CD3OD)δ(ppm): 171.0,155.8,146.9,124.2,116.6,116.2,110.7,101.1,81.9,80.2,74.1,70.7,63.1, 19.3.The isobutyric acid in step 2 of Example 1 was replaced by acetic acid, and the yield of the crude product was 98%. Compound Ib was prepared according to the remaining steps in Example 1 to obtain 5.6 g of a white solid with a purity of 98.7% and a total yield of 56% in three steps. 1 H NMR (600 MHz, CD 3 OD) δ (ppm): 7.86 (s, 1H), 6.89 (t, J=5.0 Hz, 2H), 4.87 (s, 1H), 4.43-4.41 (dd, J=12 Hz , 2.8Hz, 1H), 4.37-4.34(m, 1H), 4.30-4.27 (m, 1H), 4.13(t, J=5.7Hz, 1H), 2.03(s, 3H). 13 C NMR(150MHz, CD 3 OD)δ(ppm): 171.0, 155.8, 146.9, 124.2, 116.6, 116.2, 110.7, 101.1, 81.9, 80.2, 74.1, 70.7, 63.1, 19.3.
实施例5((2R,3S,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4二羟基四氢呋喃-2-基)丙酸甲酯的制备方法Example 5 ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3 , The preparation method of methyl ester of 4 dihydroxytetrahydrofuran-2-yl) propionate
以丙酸代替实施例1步骤2中的异丁酸,粗品收率为106%。按照实施例1中的其余各步骤反应制备化合物Ic,得到白色固体5.0g,纯度98%,三步总收率为48%。1H NMR(600MHz,CD3OD)δ(ppm):7.86(s,1H),6.90-6.88(q,J=4.5Hz, 2H),4.87-4.86(m,1H),4.46-4.43(dd,J=12Hz,2.8Hz,1H),4.37-4.36(m,1H), 4.31-4.28(m,1H),4.15(t,J=5.8Hz,1H),2.38-2.28(m,2H),1.08(t,J=7.5Hz, 3H).13C NMR(150MHz,CD3OD)δ(ppm):174.3,155.8,146.9,124.2,116.5,116.2, 110.7,101.1,82.0,80.1,74.2,70.7,62.9,26.7,7.9.The isobutyric acid in step 2 of Example 1 was replaced by propionic acid, and the crude product yield was 106%. Compound Ic was prepared according to the remaining steps in Example 1 to obtain 5.0 g of a white solid with a purity of 98% and a total yield of 48% in three steps. 1 H NMR (600 MHz, CD 3 OD) δ (ppm): 7.86 (s, 1H), 6.90-6.88 (q, J=4.5 Hz, 2H), 4.87-4.86 (m, 1H), 4.46-4.43 (dd , J=12Hz, 2.8Hz, 1H), 4.37-4.36(m, 1H), 4.31-4.28(m, 1H), 4.15(t, J=5.8Hz, 1H), 2.38-2.28(m, 2H), 1.08 (t, J=7.5Hz, 3H). 13 C NMR (150 MHz, CD 3 OD) δ (ppm): 174.3, 155.8, 146.9, 124.2, 116.5, 116.2, 110.7, 101.1, 82.0, 80.1, 74.2, 70.7 ,62.9,26.7,7.9.
实施例6((2R,3S,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4二羟基四氢呋喃-2-基)丁酸甲酯的制备方法Example 6 ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3 , The preparation method of methyl ester of 4-dihydroxytetrahydrofuran-2-yl)butyrate
以正丁酸代替实施例1步骤2中的异丁酸,粗品收率为106%。按照实施例 1中的其余各步骤反应制备化合物Id,得到白色固体6.0g,纯度97%,三步总收率为56%。1H NMR(600MHz,CD3OD)δ(ppm):7.86(s,1H),6.90-6.88(q,J=4.5 Hz,2H),4.87-4.86(m,1H),4.44-4.42(dd,J=12Hz,2.8Hz,1H),4.37-4.35(m,1H), 4.31-4.28(m,1H),4.14(t,J=5.8Hz,1H),2.32-2.23(m,2H),1.62-1.56(m,2H),0.91 (t,J=7.4Hz,3H).13C NMR(150MHz,CD3OD)δ(ppm):174.3,155.9,146.9,124.3, 116.5,116.2,110.7,101.1,82.0,80.1,74.2,70.7,62.8,35.4,17.9,12.5.The isobutyric acid in step 2 of Example 1 was replaced by n-butyric acid, and the crude product yield was 106%. The compound Id was prepared according to the remaining steps in Example 1 to obtain 6.0 g of a white solid with a purity of 97% and a total yield of 56% in three steps. 1 H NMR (600 MHz, CD 3 OD) δ (ppm): 7.86 (s, 1H), 6.90-6.88 (q, J=4.5 Hz, 2H), 4.87-4.86 (m, 1H), 4.44-4.42 (dd , J=12Hz, 2.8Hz, 1H), 4.37-4.35(m, 1H), 4.31-4.28(m, 1H), 4.14(t, J=5.8Hz, 1H), 2.32-2.23(m, 2H), 1.62-1.56 (m, 2H), 0.91 (t, J=7.4Hz, 3H). 13 C NMR (150 MHz, CD 3 OD) δ (ppm): 174.3, 155.9, 146.9, 124.3, 116.5, 116.2, 110.7, 101.1, 82.0, 80.1, 74.2, 70.7, 62.8, 35.4, 17.9, 12.5.
实施例7((2R,3S,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4二羟基四氢呋喃-2-基)壬酸甲酯的制备方法Example 7 ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3 , The preparation method of methyl 4-dihydroxytetrahydrofuran-2-yl)nonanoate
以壬酸代替实施例1步骤2中的异丁酸,粗品收率为101%。按照实施例1 中的其余各步骤反应制备化合物Ie,得到白色固体5.2g,纯度98%,三步总收率为40.3%。1H NMR(600MHz,CD3OD)δ(ppm):7.86(s,1H),6.90-6.88(q,J=4.5 Hz,2H),4.87-4.86(m,1H),4.43-4.41(dd,J=12Hz,2.8Hz,1H),4.37-4.35(m,1H), 4.32-4.29(m,1H),4.14(t,J=5.8Hz,1H),2.38-2.23(m,2H),1.56-1.53(m,2H), 1.29-1.27(m,10H),0.87(t,J=7.0Hz,3H).13C NMR(150MHz,CD3OD)δ(ppm): 173.7,155.9,146.9,124.3,116.5,116.2,110.7,101.1,82.0,74.2,70.7,62.8,33.5, 31.5,28.8,28.7,24.6,22.3.Substituting nonanoic acid for isobutyric acid in step 2 of Example 1, the crude product yield was 101%. Compound Ie was prepared according to the remaining steps in Example 1 to obtain 5.2 g of a white solid with a purity of 98% and a total yield of 40.3% in three steps. 1 H NMR (600 MHz, CD 3 OD) δ (ppm): 7.86 (s, 1H), 6.90-6.88 (q, J=4.5 Hz, 2H), 4.87-4.86 (m, 1H), 4.43-4.41 (dd , J=12Hz, 2.8Hz, 1H), 4.37-4.35(m, 1H), 4.32-4.29(m, 1H), 4.14(t, J=5.8Hz, 1H), 2.38-2.23(m, 2H), 1.56-1.53 (m, 2H), 1.29-1.27 (m, 10H), 0.87 (t, J=7.0 Hz, 3H). 13 C NMR (150 MHz, CD 3 OD) δ (ppm): 173.7, 155.9, 146.9 ,124.3,116.5,116.2,110.7,101.1,82.0,74.2,70.7,62.8,33.5, 31.5,28.8,28.7,24.6,22.3.
实施例8((2R,3S,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4二羟基四氢呋喃-2-2-乙基丁酸甲酯的制备方法Example 8 ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3 , the preparation method of 4-dihydroxytetrahydrofuran-2-2-ethylbutyric acid methyl ester
以2-乙基丁酸代替实施例1步骤2中的异丁酸,粗品收率为102%。按照实施例1中的其余各步骤反应制备化合物If,得到白色固体6.0g,纯度98.3%,三步总收率为51.3%。1H NMR(600MHz,CD3OD)δ(ppm):7.86(s,1H),6.89(s,2H), 4.87-4.86(m,1H),4.39-4.43(dd,J=12Hz,2.8Hz,1H),4.37-4.35(m,1H),4.14(t, J=5.8Hz,1H),2.38-2.22(m,1H),1.60-1.45(m,4H),0.86-0.82(m,6H).13C NMR (150MHz,CD3OD)δ(ppm):176.1,155.9,146.9,124.3,116.6,116.2,110.7,101.1, 81.9,79.9,74.2,70.7,62.8,48.9,24.7,24.6.10.7,10.6.The isobutyric acid in step 2 of Example 1 was replaced by 2-ethylbutyric acid, and the crude product yield was 102%. According to the remaining steps in Example 1, the compound If was prepared, and 6.0 g of white solid was obtained, with a purity of 98.3% and a total yield of 51.3% in three steps. 1 H NMR (600MHz, CD 3 OD) δ (ppm): 7.86 (s, 1H), 6.89 (s, 2H), 4.87-4.86 (m, 1H), 4.39-4.43 (dd, J=12Hz, 2.8Hz ,1H),4.37-4.35(m,1H),4.14(t, J=5.8Hz,1H),2.38-2.22(m,1H),1.60-1.45(m,4H),0.86-0.82(m,6H ). 13 C NMR (150MHz, CD 3 OD)δ(ppm): 176.1, 155.9, 146.9, 124.3, 116.6, 116.2, 110.7, 101.1, 81.9, 79.9, 74.2, 70.7, 62.8, 48.9, 24.7, 24.6.10.7 , 10.6.
实施例9((2R,3S,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4二羟基四氢呋喃-2-环丙烷甲酸甲酯的制备方法Example 9 ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3 , The preparation method of methyl 4-dihydroxytetrahydrofuran-2-cyclopropanecarboxylate
以环丙甲酸代替实施例1步骤2中的异丁酸,粗品收率为107%。按照实施例1中的其余各步骤反应制备化合物Ig,得到白色固体6.7g,纯度97%,三步总收率为62%。1H NMR(600MHz,CD3OD)δ(ppm):7.86(s,1H),6.89(t,J=4.5Hz, 2H),4.87-4.86(m,1H),4.46-4.44(dd,J=12Hz,2.8Hz,1H),4.36-4.34(m,1H), 4.29-4.26(m,1H),4.15(t,J=5.8Hz,1H),1.64-1.60(m,1H),0.92-0.87(m,4H).13C NMR(150MHz,CD3OD)δ(ppm):174.9,155.9,146.9,124.2,116.6,116.2,110.7, 101.1,80.2,80.1,74.2,70.6,63.0,12.1,7.5,7.4.The isobutyric acid in step 2 of Example 1 was replaced with cyclopropanecarboxylic acid, and the yield of the crude product was 107%. Compound Ig was prepared according to the remaining steps in Example 1 to obtain 6.7 g of a white solid with a purity of 97% and a total yield of 62% in three steps. 1 H NMR (600 MHz, CD 3 OD) δ (ppm): 7.86 (s, 1H), 6.89 (t, J=4.5 Hz, 2H), 4.87-4.86 (m, 1H), 4.46-4.44 (dd, J =12Hz, 2.8Hz, 1H), 4.36-4.34(m, 1H), 4.29-4.26(m, 1H), 4.15(t, J=5.8Hz, 1H), 1.64-1.60(m, 1H), 0.92- 0.87 (m, 4H). 13 C NMR (150MHz, CD 3 OD) δ (ppm): 174.9, 155.9, 146.9, 124.2, 116.6, 116.2, 110.7, 101.1, 80.2, 80.1, 74.2, 70.6, 63.0, 12.1, 7.5, 7.4.
实施例10((2R,3S,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4二羟基四氢呋喃-2-L-缬氨酸酯的制备方法Example 10 ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3 , The preparation method of 4-dihydroxytetrahydrofuran-2-L-valine ester
以Boc保护的L-缬氨酸代替实施例1步骤2中的异丁酸,柱层析收率为86%。步骤3,6N盐酸投料比换成50倍,其余步骤按照实施例1中的制备方法制备得到化合物Ih,得到近白色固体2.6g,纯度97%,三步总收率为22.2%。1H NMR (400MHz,DMSO-d6)δ(ppm):8.04(br,1H),7.92(s,1H),7.88(br,1H),6.98(d, J=4.6Hz,1H),6.85(d,J=4.5Hz,1H),6.38(br,1H),4.73(d,J=4.8Hz,1H), 4.34-4.25(m,3H),3.97(t,J=5.2Hz,1H),3.28(d,J=5.1Hz,1H),1.89-1.82(m,1H), 0.85-0.80(m,6H).The isobutyric acid in step 2 of Example 1 was replaced by Boc-protected L-valine, and the yield of column chromatography was 86%. In step 3, the feed ratio of 6N hydrochloric acid was changed to 50 times, and the remaining steps were prepared according to the preparation method in Example 1 to obtain compound Ih to obtain 2.6 g of a near-white solid with a purity of 97% and a total yield of 22.2% in three steps. 1 H NMR (400MHz, DMSO-d 6 )δ(ppm): 8.04(br, 1H), 7.92(s, 1H), 7.88(br, 1H), 6.98(d, J=4.6Hz, 1H), 6.85 (d, J=4.5Hz, 1H), 6.38 (br, 1H), 4.73 (d, J=4.8Hz, 1H), 4.34-4.25 (m, 3H), 3.97 (t, J=5.2Hz, 1H) ,3.28(d,J=5.1Hz,1H),1.89-1.82(m,1H), 0.85-0.80(m,6H).
实施例11((2R,3S,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4二羟基四氢呋喃-2-D-缬氨酸酯的制备方法Example 11 ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3 , The preparation method of 4-dihydroxytetrahydrofuran-2-D-valine ester
以Boc保护的D-缬氨酸代替实施例10中的异丁酸,经三步反应制备得到化合物Ii,得到近白色固体2.5g,纯度98%,三步总收率为21.4%。1H NMR(400 MHz,DMSO-d6)δ(ppm):7.92(s,1H),7.88(br,2H),6.92(d,J=4.2Hz,1H),6.83(d, J=4.2Hz,1H),6.34(d,J=5.6Hz,1H),5.39(s,1H),4.71(s,1H),4.33-4.17(m,3H), 3.97(s,1H),3.10(d,J=5.0Hz,1H),1.80-1.74(m,1H),0.84-0.74(m,6H).13C NMR (100MHz,DMSO-d6)δ(ppm):175.0,155.5,147.8,123.4,116.8,116.5,110.2,100.7, 81.1,78.9,73.9,70.2,63.1,59.3,31.6,19.1,17.0.Boc-protected D-valine was used to replace isobutyric acid in Example 10, and compound Ii was prepared through three-step reaction to obtain 2.5 g of a near-white solid with a purity of 98% and a three-step total yield of 21.4%. 1 H NMR (400 MHz, DMSO-d 6 ) δ (ppm): 7.92 (s, 1H), 7.88 (br, 2H), 6.92 (d, J=4.2 Hz, 1H), 6.83 (d, J=4.2 Hz, 1H), 6.34(d, J=5.6Hz, 1H), 5.39(s, 1H), 4.71(s, 1H), 4.33-4.17(m, 3H), 3.97(s, 1H), 3.10(d , J=5.0Hz, 1H), 1.80-1.74 (m, 1H), 0.84-0.74 (m, 6H). 13 C NMR (100MHz, DMSO-d 6 )δ (ppm): 175.0, 155.5, 147.8, 123.4 ,116.8,116.5,110.2,100.7, 81.1,78.9,73.9,70.2,63.1,59.3,31.6,19.1,17.0.
对比例1Comparative Example 1
向100mL三口瓶中分别加入异丁酸(0.29g,3.3mmol),EDCI(0.86g,4.5 mmol),HOBt(0.6g,4.5mmol),三乙胺(1.5g,15mmol),DCM 20mL,将反应瓶置于5-10℃冷井中搅拌,搅拌20分钟后,向反应体系中滴加入上一步缩酮保护产物(1g,3mmol)的DCM溶液(10mL)。反应16h后,HPLC显示仍旧有原料剩余,且产生含量占比40%的双酰化产物,处理,将反应液用50mL DCM稀释,有机溶液分别用1N盐酸,饱和碳酸钠,饱和食盐水洗,无水硫酸钠干燥。抽滤蒸干,柱层析得到步骤2缩合产物0.6g,收率50%。In a 100mL there-necked flask, were respectively added isobutyric acid (0.29g, 3.3mmol), EDCI (0.86g, 4.5mmol), HOBt (0.6g, 4.5mmol), triethylamine (1.5g, 15mmol), DCM 20mL, The reaction flask was placed in a cold well at 5-10°C and stirred. After stirring for 20 minutes, a DCM solution (10 mL) of the ketal-protected product (1 g, 3 mmol) in the previous step was added dropwise to the reaction system. After 16 hours of reaction, HPLC showed that there were still raw materials remaining, and a bisacylated product with a content of 40% was produced. After treatment, the reaction solution was diluted with 50 mL of DCM, and the organic solution was washed with 1N hydrochloric acid, saturated sodium carbonate, and saturated brine, respectively. Dry over sodium sulfate. Suction filtration, evaporated to dryness, and column chromatography to obtain 0.6 g of the condensation product of step 2, with a yield of 50%.
对比例2Comparative Example 2
向100mL三口瓶中加入缩酮保护产物(0.5g,1.5mmol),三乙胺(0.76g,7.5 mmol),DMAP(0.01g,0.08mmol),用10mL二氯甲烷溶解,将反应体系置于冰浴中降温,滴加异丁酸酐(0.24g,1.6mmol),滴加完毕后缓慢升至室温,继续反应7h,HPLC监测大部分转化完全,且有大量双酰化副产物产生,没有选择性,柱层析分离纯化得到5’位酯化产物0.26g,收率为43%。In a 100mL there-necked flask, add ketal protection product (0.5g, 1.5mmol), triethylamine (0.76g, 7.5mmol), DMAP (0.01g, 0.08mmol), dissolve with 10mL of dichloromethane, and place the reaction system in Cool in an ice bath, add isobutyric anhydride (0.24g, 1.6mmol) dropwise, slowly rise to room temperature after the dropwise addition, continue the reaction for 7h, HPLC monitors that most of the conversion is complete, and a large number of bisacylated by-products are produced, there is no choice was separated and purified by column chromatography to obtain 0.26 g of the 5'-esterified product with a yield of 43%.
对比例3Comparative Example 3
脱保护酸条件筛选过程的一般步骤General steps in the screening process for deprotecting acid conditions
在100mL反应器中,加入步骤2缩酮保护产物(0.2g,0.5mmol),用4mL THF溶解,于冰浴条件下缓慢加入相应的酸(12.5mmol),加毕升至室温继续反应7h,HPLC监测反应,对反应液进行处理,用碳酸氢钠调pH至7-8,加入乙酸乙酯10mL稀释,分离有机层,有机层用饱和食盐水洗,蒸干得到粗品,柱层析分离纯化。In a 100 mL reactor, the ketal protection product (0.2 g, 0.5 mmol) of step 2 was added, dissolved in 4 mL of THF, the corresponding acid (12.5 mmol) was slowly added under ice bath conditions, and the reaction was continued for 7 h after the addition was raised to room temperature. The reaction was monitored by HPLC, the reaction solution was treated, adjusted to pH 7-8 with sodium bicarbonate, diluted with 10 mL of ethyl acetate, the organic layer was separated, washed with saturated brine, evaporated to dryness to obtain the crude product, which was separated and purified by column chromatography.
ND:Not determined;a产物全部转化为GS-441524;b产物很复杂未分离;c反应在二氯甲烷介质中进行。ND: Not determined; a The product was all converted into GS-441524; b the product was very complicated and not separated; c The reaction was carried out in dichloromethane medium.
对比例4Comparative Example 4
在250mL反应器中,安装好搅拌器、温度计、恒压滴液漏斗,加入步骤2 缩酮保护产物(13.49g,0.034mol),用100mL DCM溶解,将反应瓶置于冰浴中,滴加三氟乙酸(68mL,0.918mol)。十分钟后滴加完毕,升至室温继续反应48h 后,处理,减压蒸馏去除溶剂和多余的三氟乙酸,剩余物加水,于冰浴条件下,缓慢滴加5%的氢氧化钠溶液调pH至7-8,用乙酸乙酯萃取三次,合并有机层,有机层水洗,饱和食盐水洗,硫酸钠干燥。抽滤蒸干,粗品柱层析得到7g白色固体,收率为58%,纯度:98.2%。In a 250mL reactor, install a stirrer, a thermometer, and a constant pressure dropping funnel, add the ketal protection product (13.49g, 0.034mol) of step 2, dissolve it with 100mL DCM, place the reaction flask in an ice bath, add dropwise Trifluoroacetic acid (68 mL, 0.918 mol). After ten minutes, the dropwise addition was completed, and the reaction was continued at room temperature for 48 hours. After treatment, the solvent and excess trifluoroacetic acid were removed by distillation under reduced pressure. Water was added to the residue. Under ice bath conditions, 5% sodium hydroxide solution was slowly added dropwise to adjust The pH was adjusted to 7-8, extracted three times with ethyl acetate, and the organic layers were combined, washed with water, washed with saturated brine, and dried over sodium sulfate. Suction filtration and evaporated to dryness, and the crude product was subjected to column chromatography to obtain 7 g of white solid with a yield of 58% and a purity of 98.2%.
上述实施例仅用来进一步说明本发明为(((2R,3S,4R,5R)-5-(4-氨基吡咯并 [2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4-二羟基四氢呋喃-2-异丁酸甲酯)的制备方法,但本发明并不局限于实施例,凡是依据本发明的技术实质对以上实施例所做的任何简单修饰、等同变化与修饰,均落入本发明技术方案的保护范围内。The above examples are only used to further illustrate the present invention as (((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- base)-5-cyano-3,4-dihydroxytetrahydrofuran-2-isobutyric acid methyl ester) preparation method), but the present invention is not limited to the embodiment, all according to the technical essence of the present invention to the above embodiment Any simple modifications, equivalent changes and modifications made all fall within the protection scope of the technical solution of the present invention.
Claims (8)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011613943 | 2020-12-30 | ||
| CN2020116139433 | 2020-12-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113754665A CN113754665A (en) | 2021-12-07 |
| CN113754665B true CN113754665B (en) | 2022-08-19 |
Family
ID=78787366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110621245.6A Active CN113754665B (en) | 2020-12-30 | 2021-06-03 | Preparation method of nucleoside compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113754665B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11845755B2 (en) | 2022-03-02 | 2023-12-19 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118662520A (en) | 2020-01-27 | 2024-09-20 | 吉利德科学公司 | Methods for treating SARS CoV-2 infection |
| WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| CA3179226A1 (en) | 2020-05-29 | 2021-12-02 | Tomas Cihlar | Remdesivir treatment methods |
| CR20220675A (en) | 2020-06-24 | 2023-02-15 | Gilead Sciences Inc | 1'-cyano nucleoside analogs and uses thereof |
| HUE067491T2 (en) | 2020-08-27 | 2024-10-28 | Gilead Sciences Inc | Compounds and methods for treatment of viral infections |
| KR20240093977A (en) * | 2021-11-04 | 2024-06-24 | 선전 안티브이 파마 컴퍼니 리미티드 | Crystalline form of isobutyrate nucleoside compound and method for producing the same |
| AU2022422635B2 (en) * | 2021-12-23 | 2025-09-25 | Shenzhen Antiv Pharma Co., Ltd. | Crystal form of nucleoside compound |
| WO2023186026A1 (en) * | 2022-03-31 | 2023-10-05 | 苏州旺山旺水生物医药有限公司 | Method for preparing monoisobutyryl nucleoside analog |
| CN116874491A (en) * | 2022-07-12 | 2023-10-13 | 深圳安泰维生物医药有限公司 | An N-protected pyrrolotriazine carbon glycoside compound and its preparation method |
| CN115521316B (en) * | 2022-09-23 | 2024-07-26 | 深圳安泰维生物医药有限公司 | Preparation method of nucleoside compound or intermediate thereof and intermediate of nucleoside compound |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI767201B (en) * | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | Methods for treating filoviridae virus infections |
| HUE057928T2 (en) * | 2015-09-16 | 2022-06-28 | Gilead Sciences Inc | Procedures for the treatment of infections caused by viruses belonging to the Coronaviridae family |
| WO2017184668A1 (en) * | 2016-04-20 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating flaviviridae virus infections |
| CN111961057A (en) * | 2020-05-26 | 2020-11-20 | 李小冬 | Alpha-configuration nucleoside and application thereof in treating feline coronavirus infection |
-
2021
- 2021-06-03 CN CN202110621245.6A patent/CN113754665B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| Therapeutic efficacy of the small molecule GS-5734;Travis K. Warren等;《NATURE》;20160317;第531卷;第381页 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11845755B2 (en) | 2022-03-02 | 2023-12-19 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| US11851438B2 (en) | 2022-03-02 | 2023-12-26 | Gilead Sciences, Inc. | 1′-cyano nucleoside analogs and methods for treatment of viral infections |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113754665A (en) | 2021-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113754665B (en) | Preparation method of nucleoside compound | |
| US12428442B2 (en) | Compounds, compositions and methods for synthesis | |
| US11873316B2 (en) | Compositions and methods for phosphoramidite and oligonucleotide synthesis | |
| CN114685589A (en) | Compositions and methods for phosphoramidite and oligonucleotide synthesis | |
| CN112552288A (en) | Preparation method of 4-oxime-5' - (2-methylpropionyl) uridine | |
| EP3864000A1 (en) | Synthesis of cannabigerol | |
| CN115521316B (en) | Preparation method of nucleoside compound or intermediate thereof and intermediate of nucleoside compound | |
| CN101591371B (en) | Method for preparing gemcitabine or gemcitabine analogue by halogen exchange fluorination | |
| WO2009057136A2 (en) | Epimerization by stereoselective synthesis of vitamin d analogues | |
| US9056813B2 (en) | Process for preparation of fingolimod | |
| CN118359621B (en) | Preparation method of intermediates of Li Siwei and Li Siwei and corresponding intermediates of Li Siwei | |
| CN116874491A (en) | An N-protected pyrrolotriazine carbon glycoside compound and its preparation method | |
| CN106146355B (en) | The preparation method of leonurine and aspirin conjugate | |
| CN101701027A (en) | A kind of nucleoside compound catalytic cracking method | |
| WO2006095359A1 (en) | Synthesis of 2-deoxy-2, 2-di fluoro-d-ribo furanose-3, 5 di(4-methy/4-nitro-chloro)benzoate and its conversion to gemcitabine hydrochloride thereof | |
| CN114685511A (en) | Purification method of Reidesciclovir intermediate | |
| CN111377989B (en) | Preparation method of decitabine intermediate | |
| JP5704763B2 (en) | Production of trans-4-aminocyclopent-2-ene-1-carboxylic acid derivative | |
| CN101356165A (en) | Process for preparing gemcitabine and related intermediates | |
| CN115677807A (en) | 6-position α-hydroxyalkylated purine compound and modification method thereof | |
| CN115583950A (en) | Method for modifying purine compound and 6-position acyl purine compound | |
| WO2025032082A1 (en) | Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds | |
| CN106699701A (en) | Preparation method of 1-O-methyl-2,3-dideoxy-L-arabinofuranose | |
| US20030162957A1 (en) | Protected deoxyadenosines and deoxyguanosines | |
| CN116606337A (en) | Preparation method of cordycepin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |